NCT02388464已完成1 期
A Phase 1 Clinical Pharmacology Study of the Effects of a Single 4 Hour Intravenous Infusion of Bendavia™ (MTP-131) in Subjects With Stable New York Heart Association Class II-III Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 主要终点
- Incidence of Adverse Events
研究概览
简要总结
This is a Phase 1, single-center, randomized, double-blind, single ascending dose, placebo-controlled study, in subjects aged 45-80 years with stable mild to moderate heart failure due to left ventricular systolic dysfunction, to evaluate the safety, tolerability, and pharmacokinetics of escalating single intravenous infusion doses of Bendavia™ (MTP-131).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 45 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chronic ischemic or non-ischemic cardiomyopathy of at least 6 months duration from the time of the initial diagnosis.
- •LVEF ≤35% by 2-D echocardiogram.
- •Diagnosis of NYHA Class II or III HF for a minimum of 6 months prior to the Screening Visit.
- •HF is considered to be stable and no hospitalization for HF has occurred within the previous 3 months prior to the Screening visit.
- •Treatment with appropriate pharmacologic therapy for HF including, but not limited to, angiotensin converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB), and an evidence-based beta blocker for the treatment of HF (i.e. carvedilol, bisoprolol, or extended-release metoprolol).
- •Dose and dose regimen of pharmacologic treatments for HF must be stable for a minimum of 1 month prior to the Screening Visit.
- •Females of child-bearing potential must have a negative serum pregnancy test at the Screening Visit and Day 1.
排除标准
- •LV end-diastolic dimension (LVEDD), by the same method as qualifying LVEF, is >80 mm or LVEDD indexed to body surface area is >0.
- •Unstable angina pectoris within 1 month before initiation of screening procedures. Unstable angina is defined as the occurrence of chest pain more frequently than usual, pain at rest or upon minimal exertion, or protracted episodes of pain without any discernible trigger, and/or chest pain that persists despite use of vasodilatory therapy (e.g., nitroglycerin).
- •Coronary or peripheral artery revascularization procedure within 2 months prior to the Screening Visit.
- •An acute myocardial infarction within 3 months prior to the Screening Visit.
- •Placement of an automated implantable cardioverter defibrillator (AICD) or any hardware associated with resynchronization therapy.
- •Atrial fibrillation at the Screening or Baseline Visits.
- •Uncontrolled hypertension defined as a systolic blood pressure (BP) > 180 mm Hg or a diastolic BP >110 mm Hg on at least 2 consecutive readings.
- •Requirement for valve or other cardiac surgery
- •Cardiac surgery or valvuloplasty within 2 months prior to the Screening Visit.
- •General surgery within 1 month prior to the Screening Visit
- •Restrictive cardiomyopathy, obstructive cardiomyopathy, pericardial disease, amyloidosis, infiltrative cardiomyopathy, uncorrected thyroid disease, or dyskinetic left ventricular aneurysm.
- •Cerebrovascular accident or transient ischemic attack within 3 months prior to the Screening Visit.
- •Estimated glomerular filtration rate (eGFR) <40 mL/min, using the Modification of Diet in Renal Disease (MDRD) Study equation
- •Serologic evidence of hepatitis B or C infection.
- •Known acquired immunodeficiency syndrome or HIV-positive status, or diagnosis of immunodeficiency.
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究组 & 干预措施
High dose
Experimental
干预措施: MTP-131 (Drug)
Placebo
Experimental
干预措施: Placebo (Drug)
Intermediate dose
Experimental
干预措施: MTP-131 (Drug)
Low dose
Experimental
干预措施: MTP-131 (Drug)
结局指标
主要结局
Incidence of Adverse Events
时间窗: Assessed up to Day 7
次要结局
- Left ventricular ejection fraction assessed by 2-D echocardiography(Assessed up to 24 hours post-infusion start)
研究者
相似试验
已完成
1 期
Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy AdultsSubstance-Related DisordersNCT01046539National Institute on Drug Abuse (NIDA)12
已完成
1 期
Single Ascending Dose Study of TD-1439 in Healthy SubjectsHealthy SubjectsNCT02903095Theravance Biopharma66
已完成
1 期
Single Ascending Dose Study of TD-0714 in Healthy SubjectsHealthyNCT02639078Theravance Biopharma56
已完成
1 期
A Single Dose Study of SHR0410 in Healthy Male ParticipantsAcute PainNCT03493191Atridia Pty Ltd.48
已完成
1 期
A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy VolunteersPulmonary Arterial HypertensionNCT04505137Gmax Biopharm Australia Pty Ltd.16